Share Prices & Company Research

Stockbroking

Allergy Therapeutics

Current Price 27.50p Bid 27.00p Ask 28.00p Change 0.00%
Last Updated: 22/06/2018 14:25. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Allergy Therapeutics plc is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK.

Financial Highlights Year Ended 30/06/2017

Turnover
£64.14m
Operating Profit
£-1.90m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-65.48

Key Personnel

Manuel Llobet
Chief Executive Officer
Nicolas Alexander Ulrich Wykeman
Finance Director
Peter Sinclair Jensen
Non-Executive Chairman
Dr Thomas Lander
Non-Executive Director
Stephen Rushworth Smith
Non-Executive Director
Jeffery Glen Barton
Non-Executive Director
Dr Babatunde Adekunle Otulana
Non-Executive Director

Stock Details

EPIC
AGY
ISIN
GB00B02LCQ05
Shares in Issue
594,117,768
Market cap
£163.38m

Analyst Views (2)

Strong Buy
 
50.00%
Buy
 
0.00%
Hold
 
50.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
27.50p
Bid Price
27.00p
Ask Price
28.00p
Volume
16322
Change Today
0.00p
% Change Today
0.00%
Open
27.85p
Previous Close
27.50p
Intraday High
27.85p
Intraday Low
27.50p
52 Week High
39.50p
52 Week Low
23.75p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Allergy Therapeutics Intra-day Chart

Allergy Therapeutics News

News in this section is provided by MoneyAM

Allergy Therapeutics house-dust mite immunotherapy shows positive results 29 May 2018 | 09:26 Allergy Therapeutics grass allergy product meets primary objectives 21 May 2018 | 10:05 Allergy Therapeutics losses narrow during 'abnormally weak' pollen season 07 Mar 2018 | 14:25 Allergy Therapeutics to present on 7 March 2018 at the Shares and AJ Bell Spotlight Evening in London 15 Feb 2018 | 09:24 Allergy completes recruitment in grass allergy study, results due ahead of expectations 12 Feb 2018 | 08:38 Allergy Therapeutics first-half revenue rises 4.4% 31 Jan 2018 | 14:54 Allergy Therapeutics completes recruitment for clinical study 09 Jan 2018 | 07:23 Allergy Therapeutics co-development agreement with Ergomed 12 Dec 2017 | 07:49 All resolutions passed at AGM of Allergy Therapeutics 22 Nov 2017 | 13:56 Allergy Therapeutics starts dosing for grass pollen trial 19 Oct 2017 | 09:52 Director Deals - Allergy Therapeutics PLC (AGY) 12 Oct 2017 | 15:20 Allergy Therapeutics 'continuing to gain market share' 10 Oct 2017 | 09:16 Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLC 28 Sep 2017 | 09:20 Allergy Therapeutics pre-tax losses narrow 28 Sep 2017 | 07:57 FLASH: Allergy Therapeutics operating profits up 72% 28 Sep 2017 | 07:12 Allergy Therapeutics gets approval for PQ Grass trial 18 Sep 2017 | 09:27 Allergy Therapeutics expands R&D and clinical team 11 Sep 2017 | 08:20 FLASH: Allergy Therapeutics expands R&D and clinical team 11 Sep 2017 | 07:13 Allergy Therapeutics schedules FY results 15 Aug 2017 | 09:15 Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLC 18 Jul 2017 | 09:40 Allergy Therapeutics ahead of forecasts 18 Jul 2017 | 08:04 FLASH: Allergy Therapeutics revenues up 18 Jul 2017 | 07:08

Assets (£m)

Data has been provided by MoneyAM

Reporting Date
30 Jun 2017
30 Jun 2016
Tangible Assets
9.7
9.7
Intangible Assets & Goodwill
5.5
5.4
Investments & Other Non-Current Assets
4.6
4.1
Total Non-Current Assets
19.7
19.1
Inventory
7.5
7.7
Trade & Receivables
7.9
6.5
Cash & Receivables
22.1
23.4
Other Current Assets & Assets Held for Resale
0.0
0.0
Total Assets
57.2
56.7

Liabilities (£m)

Data has been provided by MoneyAM

Reporting Date
30 Jun 2017
30 Jun 2016
Short Term Liabilities
14.0
12.5
Long Term Liabilities
13.2
13.8
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
27.2
26.4

Net Assets (£m)

Data has been provided by MoneyAM

Reporting Date
30 Jun 2017
30 Jun 2016
Net Assets
30.0
30.3

Equity (£m)

Data has been provided by MoneyAM

Reporting Date
30 Jun 2017
30 Jun 2016
Share Capital
0.6
0.6
Minority Interests
0.0
0.0
Retained Earnings
-114.4
-113.9
Share Premium Account
102.4
102.4
Other Equity
41.4
41.2
Total Equity
30.0
30.3

Cashflow (£m)

Data has been provided by MoneyAM

Reporting Date
30 Jun 2017
30 Jun 2016
Cashflow from Operating Activities
0.2
-11.8
Cashflow Before Financing
-1.8
-13.3
Increase / Decrease in Cash
-2.0
-0.8

Income (£m)

Data has been provided by MoneyAM

Reporting Date
30 Jun 2017
30 Jun 2016
Turnover
64.1
48.5
Cost of Sales
16.8
14.1
Gross Profit
47.4
34.4
Operating Profit
-1.9
-12.0
Pre-Tax Profit
-2.0
-12.1
Profit / Loss for the Year
-2.5
-13.1
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.